Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Move on then
We can go round in circles but we all know the only thing moving us from here is more info regarding trial/commercialisation or a good old fashioned pump and dump.
Not expecting either before next year tbh!
I’ve said before a few times that I think the board just uses VELA as a pension pot.
They’re 2 mil plus in the bank, they pay themselves 175k a year in salaries.
That’s well over 10 years of guaranteed income without lifting a finger, regardless of how well or how poorly any of the investments go.
I reduced my holding here weeks ago and have been fortunate enough to recuperate my losses by selling, but I had such high hopes for this, in particular the AZD1656. The board seemed uninterested, don’t communicate, update us or invest spare capital. A personal cash cow. I’ll probably be called a deramper again, but it is what it is as far as I can see.
When the trial ended, Vela did not release an RNS. The news came from the SGS website and twitter.
I understand that Vela are letting each company release their own news and updates. That's fine, but how is that supposed to put Vela on other people's radars. I check the RNS releases most days to see if there is anything interesting. For example is you had seen the Code RNS this morning it might make you invest in CODE not Vela. We are hardly increasing the value of our own SP by increased value in our investment portfolio. I am really not sure what the 3 board members are doing for Vela. They are being paid a wage but for what. Surely it only takes 1 person to pick our once every 6 month investment. We took another board member on recently, what has she brought to the party. Starting to wonder why I am still holding this dog of a share.
This is what I was saying.. Our board is the literal opposite of Modes. Mode will lie in an RNS to get news flow, we have news but don't release it!
Maybe the £2m has been deployed & they just can't be ars5d knocking out an RNS!
We knew there was another investment earlier this year but did not know the details. Only in the Final Results did Vela disclose an investment in Rural Broadband Solutions PLC that was made 12 months earlier in Oct 2020. How can an Investment company not disclose an investment for a whole year? Haven't even bothered to add this (or CODE) to the website investments list yet after all this time. Why they would want to invest a small amount in an illiquid stock listed on Aquis is a whole other issue.
Agree completely. Undoubtedly the comms from the board is terrible. feels like an age since our last investment and we have £2m in the account! As SH we need to know what is going on and the SP being where it is is not doing any favours to the LTH.
I agree that they just don't seem bothered in Vela. We have a sizeable amount of money just sat in the bank. Are they bothering to research and find more Codes. I would say their interests are else where. JN has thrown all our eggs into one basket. If the SGS trial is a bust the so will Velas SP for quite some time.
This is a wider issue than SGS Trial. The BoD are ineffective and quite frankly seem disinterested. They have done nothing all year to instil any confidence for the SHs to hang onto.
My assumption, in the absence of negative news, is that commercialisation discussions are going on under NDAs whilst the trial is peer reviewed. A positive peer review and things will jump forward massively and quickly .
I agree communication has been poor regarding the trial. I can only point you in the direction of SNG RNS - https://www.lse.co.uk/rns/SNG/positive-results-from-trial-in-covid-19-patients-fihvg7kkd3390v1.html
No mention of peer review in their RNS either but of course peer review was required. There are negatives if we compare SGS results to SNG, statistical data and lots of it! SGS used words like 'strong trend' etc whereas SNG had statistics to back up their words. Until we see statistical results of the trial (assuming in a peer review) SGS positive words are just that.. words.
Remember VELA are just invested in the trial whereas SNG own their drug.
Also from the 18th December RNS. Its very clearly written that a deal would expected to be agreed almost immidiately. Once again, where is the mention of the peer review. SGS and Vela need to update us exactly what is happening. I stand by my original comment. The lack of an update is a disgrace from all involved.
This gives AZD1656 longevity as a treatment beyond the current pandemic. AZD1656 is an orally available tablet that is stable at room temperature, making it suitable for use around the world. Furthermore, should the trial be successful, we expect to agree a commercial deal with a partner almost immediately."
Where exactly in the below RNS has a peer review Neen mentioned.
Further to the update released by Vela on 6 September 2021, the Board of Vela has been informed by St George Street Capital ("SGSC") that, following receipt of the final data from the ARCADIA Phase II clinical trial, SGSC will immediately start to undertake commercial discussions with potential licensees and/or fundraise for further clinical trials to investigate SGS002 ("the Asset") in a larger study. Further analysis to determine the precise nature of the biological effects of the Asset that explain the observed clinical outcomes will also be conducted.
There has been no mention of a Peer Review in an RNS. It was first highlighted in the 20 Sept UCL article, without which we would be none the wiser ourselves. The RNS mentioned immediate commercial licence discussions and/or fundraising for further clinical trials. If a Peer Review is a pre-condition, then Vela should provide an update as the general market most likely unaware of this.
They can’t update until peer review completed
Code is certainly performing well so far. Exactly the kind of share I would not normally look at but JN obviously seen the potential.
Shame he is prehistoric with his communication. Getting very bored waiting on anything from SGS as well. The lack of updates is shocking. Butter it up however you like but to have heard nothing from September is a disgrace.
Continues to forge ahead and appears a very good investment